ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc (SNOA)

0.1826
0.0175
( 10.60% )
Updated: 13:33:49

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.1826
Bid
0.1825
Ask
0.184
Volume
2,850,959
0.15 Day's Range 0.1919
0.1159 52 Week Range 1.52
Market Cap
Previous Close
0.1651
Open
0.1575
Last Trade
1
@
0.184
Last Trade Time
13:40:13
Financial Volume
$ 517,524
VWAP
0.181526
Average Volume (3m)
2,017,482
Shares Outstanding
15,607,433
Dividend Yield
-
PE Ratio
-0.58
Earnings Per Share (EPS)
-0.33
Revenue
13.27M
Net Profit
-5.15M

About Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of ther... Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes and others. The company derives revenue from the sale of products in the United States, Latin America, Europe and other countries. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
Sonoma Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SNOA. The last closing price for Sonoma Pharmaceuticals was $0.17. Over the last year, Sonoma Pharmaceuticals shares have traded in a share price range of $ 0.1159 to $ 1.52.

Sonoma Pharmaceuticals currently has 15,607,433 shares outstanding. The market capitalization of Sonoma Pharmaceuticals is $2.97 million. Sonoma Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.58.

SNOA Latest News

Form 8-K - Current report

false 0001367083 0001367083 2024-03-08 2024-03-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Filed Pursuant to Rule 424(b)(3) Registration No. 333-275311   PROSPECTUS SUPPLEMENT (to Prospectus dated November 22, 2023)     Up to $785,679   SONOMA...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

false --03-31 2024 Q3 0001367083...

Form 8-K - Current report

false 0001367083 0001367083 2024-01-10 2024-01-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES...

Form 8-K - Current report

false 0001367083 0001367083 2024-01-05 2024-01-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.04330.80229226360.13960.19190.132213087630.1590206CS
40.032421.57123834890.15020.19190.13115741410.15348212CS
12-0.006-3.181336161190.18860.31080.131120174820.18190285CS
26-0.6079-76.90069576220.79050.8189530.115914611040.18979428CS
52-0.9174-83.41.11.520.11598965490.39483666CS
156-6.7074-97.34978229326.8913.360.11599358103.49875013CS
260-0.7524-80.47058823530.93519.540.11596748514.41129866CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 21.29
(348.21%)
21.92M
XLOXilio Therapeutics Inc
$ 1.47
(130.05%)
28.7M
CEROCERo Therapeutics Holdings Inc
$ 2.999
(83.99%)
16.29M
BDRXBiodexa Pharmaceuticals PLC
$ 1.47
(71.13%)
82.21M
KYCHKeyarch Acquisition Corporation
$ 11.7401
(67.59%)
160.47k
BOLDBoundless Bio Inc
 14.76
(-75.39%)
499k
PMECPrimech Holdings Ltd
$ 1.39
(-64.18%)
6.08M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
GMDAGamida Cell Ltd
$ 0.037401
(-36.82%)
66.07M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.2239
(-31.51%)
15.23M
NKLANikola Corporation
$ 1.0298
(13.28%)
131M
BDRXBiodexa Pharmaceuticals PLC
$ 1.47
(71.13%)
82.21M
MARAMarathon Digital Holdings Inc
$ 22.92
(3.85%)
67.21M
GMDAGamida Cell Ltd
$ 0.037401
(-36.82%)
66.07M
AKANAkanda Corporation
$ 0.1599
(-3.03%)
64.68M

SNOA Discussion

View Posts
TheFinalCD TheFinalCD 3 months ago
.16-.25

$1.7M OFFERING @ .20
https://dilutiontracker.com/app/search/SNOA
๐Ÿ‘๏ธ0
OffTheGrid OffTheGrid 4 months ago
😁
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
SNOA new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
SNOA new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
SNOA new 52 week low
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 9 months ago
hmmm
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 9 months ago
nice
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 10 months ago
dip;
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 10 months ago
Coming back around Cool
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 10 months ago
nice
๐Ÿ‘๏ธ0
The Night Stalker The Night Stalker 10 months ago
nice
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 10 months ago
SNOA: Hey, Cpt. T-N!!! (I indeed DID get your PM, but --- since I no longer have a subscription to that --- I can only reply to you right here. In any event, THANKS Bro for your heads-up!!)

And let's get this Big Dog FLYIN'!!!!
๐Ÿ‘๏ธ0
Triple nickle Triple nickle 10 months ago
Continuing higher from PM
๐Ÿ‘๏ธ0
alchemytrader alchemytrader 12 months ago
There is no other symbol. The other one is s private company.
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
$SNOA being confused with a different Sonoma regarding $REGN deal— t.k. (@tcarm1) March 28, 2023
๐Ÿ‘๏ธ0
zj3001 zj3001 1 year ago
The other is private company partnering with REGN
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
WHATS THE OTHER SYMBOL?
๐Ÿ‘๏ธ0
alchemytrader alchemytrader 1 year ago
people chased off news from the WRONG TICKER...lol
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
https://finviz.com/quote.ashx?t=SNOA&p=d
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
Nice premarket gap up
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
Nice AH move
๐Ÿ‘๏ธ0
Toddrobertking Toddrobertking 1 year ago
Sonoma Pharmaceuticals managed to land one serious new customer: the United States government. Sonomaโ€™s Microcyn Rx line of products now have a DAPA, or a Distribution and Pricing Agreement. This opens up their use for the Defense Logistics Agency. This also gives Sonomaโ€™s partner, EMC Pharma, the ability to offer Microcyn Rx products to its own customers in the U.S. government. Half of EMC Pharmaโ€™s customer base is U.S. government entities. That, in turn, likely means a nice shot in the profits for Sonomaโ€™s partner firm.
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
OS only 3+milly
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
Buy 2โ€™s up!
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
2.68 finally broke $2.44 without meeeeeeeeee

#ARRRRRRRRG

after taking it down to 1.88
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
im out with profits on the fail to break new ni
๐Ÿ‘๏ธ0
resx18 resx18 1 year ago
Good Morning $SNOA
👍️ 1
TheFinalCD TheFinalCD 1 year ago
break 2.44 run to 2.75+
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
trying again for 2.44
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
$SNOA watch for 2.44 break tried 2x already
๐Ÿ‘๏ธ0
tw0122 tw0122 1 year ago
$2.10 Ran to quick for me might have to pass unless it pulls back some 2.2 million float could do more wonders.
Good luck
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
$SNOA https://twitter.com/algobotnews/status/1618227346275794944

https://finviz.com/quote.ashx?t=SNOA&ty=c&ta=1&p=d
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 1 year ago
3M os lets see how it goes https://finviz.com/quote.ashx?t=SNOA&ty=c&ta=1&p=d
๐Ÿ‘๏ธ0
subslover subslover 1 year ago
Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States
Download as PDFOctober 27, 2022
BOULDER, CO / ACCESSWIRE / October 27, 2022 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care and dermatological conditions, today announced that it has launched Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn® Advanced Skin Repair Cooling Mist direct to consumers for over-the-counter use in the United States.

Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel is a new direct to consumer version of a product previously only available by prescription. Reliefacyn alleviates symptoms such as red bumps, itchy, painful and scaly rashes, shallow skin fissures and peeling, and effectively manages symptoms of eczema/atopic dermatitis. Reliefacyn supports the three phases of healing (inflammation, proliferation and remodeling), and the gel adheres quickly to the skin, making it easy to apply without dripping or running. Reliefacyn is antipruritic, anti-inflammatory, and anti-allergic.

Rejuvacyn® Advanced Skin Repair Cooling Mist is intended for over-the-counter management of minor skin irritations following cosmetic procedures as well as daily skin health and hydration. Formulated to enhance the body's natural healing process, Rejuvacyn aids in recovery following common procedures performed at dermatologists' offices and medical spas such as microdermabrasion, laser treatments, injections, facials, and chemical peels. Rejuvacyn is safe to use around the nose, mouth, and eyes, with a cool mist application that soothes the skin. Rejuvacyn® Advanced Skin Repair Cooling Mist has also been certified as a Natural Personal Care Product by the Natural Products Association.

"We are excited to expand our line of dermatology products to create a portfolio of consumer-focused products that provide healing and relief for common conditions and procedures. We've also formulated Rejuvacyn as an all-natural product for consumers who want to avoid potentially harmful additives in their healthcare regime. Our products will be immediately available through our website, and through third-party distributors," said Amy Trombly, CEO of Sonoma Pharmaceuticals.

For more information about these products, visit https://sonomapharma.com/dermatology-new. You can order Reliefacyn or Rejuvacyn on our website at https://otc.sonomapharma.com or by contacting our customer service department at 720-452-9690 or customerservice@sonomapharma.com.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, and dermatological conditions. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company's products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within
๐Ÿ‘๏ธ0
stocktrader306 stocktrader306 2 years ago
been a long time since i visited this board. but i'm still accumulating SNOA!!! hoping some news comes to do what it did last August !????????????????
๐Ÿ‘๏ธ0
wile.e.coyote wile.e.coyote 2 years ago
lo floater on news .....
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 2 years ago
So,so news. No $ contracts announced. News catalyst for day trade.
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 2 years ago
does SNOA ran more on this hand sanitizer news, hold or fall back?


๐Ÿ‘๏ธ0
PStockPickz PStockPickz 2 years ago
Going straight up!
๐Ÿ‘๏ธ0
PStockPickz PStockPickz 2 years ago
$SNOA news is nothing special but the float already traded in premarket. Could be a serious squeeze here— M K (@pennystockpickz) October 15, 2021
๐Ÿ‘๏ธ0
PStockPickz PStockPickz 2 years ago
I noticed your first on the scene for a lot of these runners. Congrats !
๐Ÿ‘๏ธ0
PStockPickz PStockPickz 2 years ago
O/s 2.09m short float 39%
๐Ÿ‘๏ธ0
PStockPickz PStockPickz 2 years ago
Could be a huge runner today
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 2 years ago
Sonoma Pharma, MicroSafe Report Nanocyn Disinfectant, Sanitzer Has Been Approved By Australia Therapeutic Goods Admin.
7:04 am ET October 15, 2021 (Benzinga) Print
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonomaโ€™s patented Microcyn® Technology.

After original approval by the TGA and entry into The Australian Register Of Therapeutic Goods for use against SARS-CoV-2 (COVID 19) in mid-2020, the TGA has now approved extended claims for the hard-surface disinfectant Nanocyn® with a 15 second kill time against common viruses, including SARS-CoV-2, Norovirus (Gastro), and influenza, and a 30-second kill contact time against common bacteria, such as Staphylococcus aureus (MRSA), E. coli, Pseudomonas aeruginosa, fungi and mold - including Candida Albicans.

โ€œNanocyn® is a game-changer for any hospital, aged care or health care facility, transportation-provider, business, school, tourism or hospitality venue wanting to ensure their premises are COVID-safe, not just from a pandemic point of view, but also the comfort that comes with using a non-toxic disinfectant that does not leave any harmful residues behind,โ€ said MicroSafe Group CEO Safa Qadumi.

In addition, Nanocyn® had been previously certified by major aviation manufacturers. The product can disinfect aircraft without damaging sensitive materials. It is also the only TGA registered hospital grade disinfectant of its kind to be certified by Good Environmental Choice Australia (GECA).

Bruce Thornton, Chief Operating Officer of Sonoma Pharmaceuticals stated, โ€œWe could not be more excited about making our safe and effective Microcyn® Technology available to valued partners such as MicroSafe. We are continuously seeking to add to our network of international distributors to increase the reach of Sonoma products worldwide.โ€

๐Ÿ‘๏ธ0
Surfacetite Surfacetite 2 years ago
can we please get back to premarket levels
๐Ÿ‘๏ธ0
Get-Rich Get-Rich 2 years ago
Nice$
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 2 years ago
Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has announced the OTC consumer launch of Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser on Amazon.com and MucoClyns on Amazon sites in Europe.
All three products are based on Sonoma's Microcyn technology and are immediately available for customer orders.
The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel.
Regenacyn Advanced Scar Gel is used to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation.
Ocucyn Eyelid & Eyelash Cleanser, designed for everyday use, is a safe, gentle & effective solution for eyelid & eyelash hygiene.
MucoClyns is a personal decontamination solution for the face and skin. It can be used on mucous membranes, cuts, abrasions, burns, and body surfaces to clean and treat immediately after unexpected exposure to infection risk.
Also Read: Sonoma Stock Doubles On Launch Of Two Dental Products.
Price Action: SNOA stock is up 70.30% at $9.11 during the premarket session on the last check Tuesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 2 years ago
9.30'S

snoa
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 2 years ago
Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe
7:00 am ET September 28, 2021 (BusinessWire) Print
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter ("OTC") consumer launch of Regenacyn(R) Advanced Scar Gel and Ocucyn(R) Eyelid & Eyelash Cleanser on Amazon.com, and MucoClyns(TM) on Amazon sites in Europe. All three products are based on Sonoma's patented Microcyn(R) technology and are immediately available for customer orders.

Sonoma is pleased to offer its superior, safe and effective hypochlorous acid products directly to consumers. For years, Sonoma has offered its products as prescription or office dispense products available only from physicians. The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel that makes its proven Microcyn(R) technology widely available for all.

Regenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.

Ocucyn Eyelid & Eyelash Cleanser, designed for everyday use, is a safe, gentle & effective solution for good eyelid & eyelash hygiene. Ocucyn Eyelid & Eyelash Cleanser helps clean dirty and crusty irritated eyelids. Ocucyn Eyelid & Eyelash Cleanser is steroid free, non-irritating, non-cytotoxic, non-sensitizing and requires no special handling.

MucoClyns is a personal decontamination solution for the face and skin. MucoClyns is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces to clean and treat immediately after unexpected exposure to infection risk. MucoClyns is biocompatible for its indicated use and safe and non-irritating to human skin.

Regenacyn(R) Advanced Scar Gel is available for purchase here and Ocucyn(R) Eyelid & Eyelash Cleanser is available for purchase here. For more information, please also visit Sonoma's U.S. website.

MucoClyns(TM) is available at Amazon UK, Germany, France, Italy, and Spain. For more information please also visit the Sonoma Europe website.

Amy Trombly, Chief Executive Officer of Sonoma Pharmaceuticals stated, "we could not be more excited about making our safe and effective products available directly to consumers through Amazon. We look forward to offering our clinically proven and patented Microcyn(R) Technology to a wider range of patients for advanced scar management, eyelid & eyelash hygiene and personal protection spray for the face and skin."

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company's products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals(TM), Microcyn(R), Regenacyn(R), MucoClyns(TM), and Ocucyn(R) are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005356/en/

SOURCE: Sonoma Pharmaceuticals, Inc.
๐Ÿ‘๏ธ0
crudeoil24 crudeoil24 2 years ago
SNOA is a great $$$$$ opportunity.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock